Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet’s disease

Abstract Background Behçet’s disease (BD) is a systemic inflammatory disease that involves various organs. The clinical manifestation-based diagnosis of BD is a time-consuming process, which makes it difficult to distinguish from patients with similar symptoms. Moreover, an authentic biomarker has n...

Full description

Bibliographic Details
Main Authors: Soo Jin Park, Mi Jin Park, Sun Park, Eun-So Lee, Do Yup Lee
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Arthritis Research & Therapy
Subjects:
Online Access:https://doi.org/10.1186/s13075-022-02986-5
_version_ 1797958534297550848
author Soo Jin Park
Mi Jin Park
Sun Park
Eun-So Lee
Do Yup Lee
author_facet Soo Jin Park
Mi Jin Park
Sun Park
Eun-So Lee
Do Yup Lee
author_sort Soo Jin Park
collection DOAJ
description Abstract Background Behçet’s disease (BD) is a systemic inflammatory disease that involves various organs. The clinical manifestation-based diagnosis of BD is a time-consuming process, which makes it difficult to distinguish from patients with similar symptoms. Moreover, an authentic biomarker has not been developed for accurate diagnosis yet. Our current study investigated the unique metabolic signatures of BD and explored biomarkers for precise diagnosis based on an untargeted metabolomic approach. Methods Integrative metabolomic and lipidomic profiling was performed on plasma samples of BD patients (n = 40), healthy controls (HCs, n = 18), and disease controls (DCs, n = 17) using GC-TOF MS and LC-Orbitrap MS. Additionally, the lipid profiles of 66 peripheral blood mononuclear cells (PBMCs) were analyzed from 29 BD patients, 18 HCs, and 19 DCs. Results Plasma metabolic dysfunction in BD was determined in carbohydrate, hydroxy fatty acid, and polyunsaturated fatty acid metabolisms. A plasma biomarker panel with 13 compounds was constructed, which simultaneously distinguished BD from HC and DC (AUCs ranged from 0.810 to 0.966). Dysregulated PBMC metabolome was signatured by a significant elevation in lysophosphatidylcholines (LPCs) and ether-linked lysophosphatidylethanolamines (EtherLPEs). Ten PBMC-derived lipid composites showed good discrimination power (AUCs ranged from 0.900 to 0.973). Correlation analysis revealed a potential association between disease activity and the metabolites of plasma and PBMC, including sphingosine-1 phosphate and EtherLPE 18:2. Conclusions We identified metabolic biomarkers from plasma PBMC, which selectively discriminated BD from healthy control and patients with similar symptoms (recurrent mouth ulcers with/without genital ulcers). The strong correlation was determined between the BD activity and the lipid molecules. These findings may lead to the development for diagnostic and prognostic biomarkers based on a better understanding of the BD pathomechanism.
first_indexed 2024-04-11T00:20:23Z
format Article
id doaj.art-0bbf52766b604b9f82dc7c1dec0a5baf
institution Directory Open Access Journal
issn 1478-6362
language English
last_indexed 2024-04-11T00:20:23Z
publishDate 2023-01-01
publisher BMC
record_format Article
series Arthritis Research & Therapy
spelling doaj.art-0bbf52766b604b9f82dc7c1dec0a5baf2023-01-08T12:17:33ZengBMCArthritis Research & Therapy1478-63622023-01-0125111310.1186/s13075-022-02986-5Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet’s diseaseSoo Jin Park0Mi Jin Park1Sun Park2Eun-So Lee3Do Yup Lee4Department of Agricultural Biotechnology, Seoul National UniversityDepartment of Dermatology, Ajou University School of MedicineDepartment of Microbiology, Ajou University School of MedicineDepartment of Dermatology, Ajou University School of MedicineDepartment of Agricultural Biotechnology, Seoul National UniversityAbstract Background Behçet’s disease (BD) is a systemic inflammatory disease that involves various organs. The clinical manifestation-based diagnosis of BD is a time-consuming process, which makes it difficult to distinguish from patients with similar symptoms. Moreover, an authentic biomarker has not been developed for accurate diagnosis yet. Our current study investigated the unique metabolic signatures of BD and explored biomarkers for precise diagnosis based on an untargeted metabolomic approach. Methods Integrative metabolomic and lipidomic profiling was performed on plasma samples of BD patients (n = 40), healthy controls (HCs, n = 18), and disease controls (DCs, n = 17) using GC-TOF MS and LC-Orbitrap MS. Additionally, the lipid profiles of 66 peripheral blood mononuclear cells (PBMCs) were analyzed from 29 BD patients, 18 HCs, and 19 DCs. Results Plasma metabolic dysfunction in BD was determined in carbohydrate, hydroxy fatty acid, and polyunsaturated fatty acid metabolisms. A plasma biomarker panel with 13 compounds was constructed, which simultaneously distinguished BD from HC and DC (AUCs ranged from 0.810 to 0.966). Dysregulated PBMC metabolome was signatured by a significant elevation in lysophosphatidylcholines (LPCs) and ether-linked lysophosphatidylethanolamines (EtherLPEs). Ten PBMC-derived lipid composites showed good discrimination power (AUCs ranged from 0.900 to 0.973). Correlation analysis revealed a potential association between disease activity and the metabolites of plasma and PBMC, including sphingosine-1 phosphate and EtherLPE 18:2. Conclusions We identified metabolic biomarkers from plasma PBMC, which selectively discriminated BD from healthy control and patients with similar symptoms (recurrent mouth ulcers with/without genital ulcers). The strong correlation was determined between the BD activity and the lipid molecules. These findings may lead to the development for diagnostic and prognostic biomarkers based on a better understanding of the BD pathomechanism.https://doi.org/10.1186/s13075-022-02986-5MetabolomicsLipidomicsBehçet’s diseaseAutoimmune disease
spellingShingle Soo Jin Park
Mi Jin Park
Sun Park
Eun-So Lee
Do Yup Lee
Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet’s disease
Arthritis Research & Therapy
Metabolomics
Lipidomics
Behçet’s disease
Autoimmune disease
title Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet’s disease
title_full Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet’s disease
title_fullStr Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet’s disease
title_full_unstemmed Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet’s disease
title_short Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet’s disease
title_sort integrative metabolomics of plasma and pbmcs identifies distinctive metabolic signatures in behcet s disease
topic Metabolomics
Lipidomics
Behçet’s disease
Autoimmune disease
url https://doi.org/10.1186/s13075-022-02986-5
work_keys_str_mv AT soojinpark integrativemetabolomicsofplasmaandpbmcsidentifiesdistinctivemetabolicsignaturesinbehcetsdisease
AT mijinpark integrativemetabolomicsofplasmaandpbmcsidentifiesdistinctivemetabolicsignaturesinbehcetsdisease
AT sunpark integrativemetabolomicsofplasmaandpbmcsidentifiesdistinctivemetabolicsignaturesinbehcetsdisease
AT eunsolee integrativemetabolomicsofplasmaandpbmcsidentifiesdistinctivemetabolicsignaturesinbehcetsdisease
AT doyuplee integrativemetabolomicsofplasmaandpbmcsidentifiesdistinctivemetabolicsignaturesinbehcetsdisease